Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2CNS 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Parathyroid Neoplasms 1Parathyroid Diseases 1Opioid-Related Disorders 1Goiter 1Agnosia 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Capsules × Head & Neck × Clear all
NCT03469310 2021-05-11

Minimizing Narcotic Analgesics After Endocrine Surgery

DHR Health Institute for Research and Development

Phase 4 Completed
126 enrolled
Head & Neck

Agnosia, Goiter, Opioid-Related Disorders, Parathyroid Diseases, Parathyroid Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Thyroid Nodule

Data powered by HemOnc (CC BY 4.0) Colophon âš¡